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Abstract
Background: Mitochondrial dysfunction and oxidative stress are central mechanisms underlying the aging process and the
pathogenesis of many age-related diseases. Selected antioxidants and specific combinations of nutritional compounds
could target many biochemical pathways that affect both oxidative stress and mitochondrial function and, thereby,
preserve or enhance physical performance.
Methodology/Principal Findings: In this study, we evaluated the potential anti-aging benefits of a Q-terH based nutritional
mixture (commercially known as EufortynH) mainly containing the following compounds: terclatrated coenzyme Q10 (Q-
terH), creatine and a standardized ginseng extract. We found that EufortynH supplementation significantly ameliorated the
age-associated decreases in grip strength and gastrocnemius subsarcolemmal mitochondria Ca
2+ retention capacity when
initiated in male Fischer344 x Brown Norway rats at 21 months, but not 29 months, of age. Moreover, the increases in
muscle RNA oxidation and subsarcolemmal mitochondrial protein carbonyl levels, as well as the decline of total urine
antioxidant power, which develop late in life, were mitigated by EufortynH supplementation in rats at 29 months of age.
Conclusions/Significance: These data imply that EufortynH is efficacious in reducing oxidative damage, improving the age-
related mitochondrial functional decline, and preserving physical performance when initiated in animals at early midlife (21
months). The efficacy varied, however, according to the age at which the supplementation was provided, as initiation in late
middle age (29 months) was incapable of restoring grip strength and mitochondrial function. Therefore, the EufortynH
supplementation may be particularly beneficial when initiated prior to major biological and functional declines that appear
to occur with advancing age.
Citation: Xu J, Seo AY, Vorobyeva DA, Carter CS, Anton SD, et al. (2010) Beneficial Effects of a Q-terH Based Nutritional Mixture on Functional Performance,
Mitochondrial Function, and Oxidative Stress in Rats. PLoS ONE 5(5): e10572. doi:10.1371/journal.pone.0010572
Editor: Alejandro Lucia, Universidad Europea de Madrid, Spain
Received December 23, 2009; Accepted April 16, 2010; Published May 11, 2010
Copyright:  2010 Xu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Pharmaland SA, grants to CL from the National Institute on Aging (AG17994), the University of Florida Institute on Aging
and the Claude D. Pepper Older Americans Independence Center National Institutes of Health Grant (1 P30 AG028740), fellowship awards from the American
Heart Association to JX (09POST2060112) and SDA (09CRP2390173 and 1K23AT004251), and a University Scholars Program award from the University of Florida
Honors Program to DAV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors declare that they have no employment, consultancy, patents, products in development or marketed products with the
company Pharmaland SA. The authors also declare that the following patent is not relevant to the article: Patent No: US 6,541,265 B2; Date of Patent Apr. 1, 2003.
‘‘Method and system to test a substance for inflammatory or oxidant properties’’. Inventor: Christiaan Leeuwenburgh. Assignee: University of Florida, Gainesville,
Florida (United States); Application No. 09/852,194; Filed May 9, 2001.
* E-mail: jxu@aging.ufl.edu (JU); cleeuwen@aging.ufl.edu (CL)
Introduction
Mitochondrial dysfunction and oxidative stress are recognized
as fundamental driving mechanisms of aging [1–3]. The aging
process results in an accelerated decline of functional performance
including a decline in physiological function and reduced physical
activity [4]. The exact mechanisms that cause this functional
decline are not fully understood; however, the mitochondrial free
radical theory of aging has gained strong support [1,5,6]. With
advancing age, oxidative damage (e.g. mtDNA mutations)
accumulates in individual cells; eventually some cells reach the
point at which the mitochondrial energy generation system is
seriously impaired. When the impairment of mitochondrial
bioenergetics occurs in a significant number of cells within a
tissue, the function of the tissue is compromised and consequently
contributes to age-related pathologies. Since mitochondrial
dysfunction and aging are mediated by a number of biochemical
pathways, interventions that target multiple pathways through
combination therapies may be more efficacious than therapies that
only target one pathway [7–9].
Nutritional based interventions are becoming more popular
among consumers and specific combinations of nutritional
interventions may effectively bypass electron transport chain
defects, provide alternative energy sources, and act as antioxidants
as well [7–9]. Thus, specific nutritional mixtures may have the
potential to reduce oxidative stress, prevent mitochondrial
functional decline, and preserve performance. Three specific
compounds that have been found to affect both oxidative stress
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and ginseng. These compounds may act in a synergistic manner
when combined.
Coenzyme Q10 (CoQ10) has long been known for its key role in
mitochondrial bioenergetics and prescribed for chronic fatigue
syndrome [10,11]. In its reduced form, it is known as ubiquinol, a
potent lipophilic antioxidant [12]. CoQ10 is a component of the
electron transport chain and is associated with inner mitochondrial
complex III protein and participates in aerobic cellular respiration
[13,14]. It is also located in membranes in close proximity to the
unsaturated lipid chains to act as a primary scavenger of free
radicals [15]. Also it is recognized as a modulator of mitochondrial
permeability transition, which is associated with the mitochondria-
mediated apoptosis and cell death [16,17]. The opening of
permeability transition pores (PTP) in the inner mitochondrial
membrane can lead to mitochondrial swelling and dysfunction,
causing cell death [18–20]. CoQ10 appears to exert its protective
effect by inhibiting the mitochondrial PTP opening [21–23].
Moreover, CoQ10 is a cofactor of mitochondrial uncoupling
proteins and may also exert protective effects by activation of these
proteins, leading to a reduction in mitochondrial-free radical
generation [24,25]. Protective effects of CoQ10 against oxidative
stress and mitochondrial dysfunction have been demonstrated in
several in vitro and in vivo models [21,26–30]. The capability of
CoQ10 to trigger mitochondrial function is thus grounded on
sound biochemical evidence. However, its use in humans as a
therapeutic agent proved unsatisfactory, most likely because of its
poor solubility in water, its limited solubility in lipids, and its
relatively high molecular weight (863 g/mol), all result in poor oral
bioavailability [31,32]. For example, in one study in rats it was
reported that only about 2–3% of orally administered CoQ10 was
absorbed [33]. Recently, a mechano-physical procedure called
terclatration was developed, whereby CoQ10 is rendered highly
water soluble without chemical modification of the moiety [34].
The resultant multicomposite, Q-terH, can be shown to be 3- to 5-
fold more bioavailable in humans, as compared to native CoQ10
[34]. Fetoni et al. reported that water-soluble Q-terH shows an
improved ability versus normal CoQ10 in preventing oxidative
damage and mitochondrial dysfunction in noise-induced hearing
loss in guinea pigs [31].
The two other compounds utilized in EufortynH are creatine
and ginseng each targeting different biological pathways [35,36].
Creatine supplementation was initially used as an ergogenic aid to
increase the phosphocreatine pool within muscle to bolster athletic
performance [37–40]. It has been also reported to act as an
antioxidant against reactive species ions, e.g. superoxide anions
(ON
2
2) and peroxynitrite (OONO
2) [41], and enhance expression
of myogenin and other myogenic regulatory factors that regulate
myosin heavy chain expression as well [42,43]. However, creatine
supplementation has recently been recognized as a potential
intervention to various neurodegenerative disorders targeting
bioenergetic failure observed in these conditions [44,45]. For
example, creatine has been found to be useful in buffering
intracellular energy stores and reducing the cellular energy deficit
by improving mitochondrial function and to be effective in
attenuating the age-related decline in mitochondrial function [44].
Creatine has also been shown to inhibit mitochondrial perme-
ability transition and enhance mitochondrial function in stimulat-
ing mitochondrial energy production via creatine-stimulated
respiration and the adenine nucleotide translocase [35,46].
Moreover, ginseng is a potent antioxidant and has been
extensively used to reduce oxidative damage and prevent age-
related diseases [47–49]. Ginsenosides, the major active ingredi-
ents of ginseng, are steroidal saponins with different sugar moieties
[50]. To date more than 30 types of ginsenosides have been
isolated and identified [51]. In particular, ginsenoside Rb1 and
Rg1 are considered to be the most effective compounds in ginseng
extracts [48,52]. Various studies provide compelling evidence that
ginseng extracts possess mitochondria protective capacity by
inhibiting mitochondrial swelling and preserving mitochondrial
membrane integrity in rodents [36,53,54].
In this study, we evaluated the potential effects of a nutritional
mixture mainly containing Q-terH, creatine and a Rg1 titrated
ginseng extract (the mixture is commercially known as EufortynH)
using Fischer 344 x Brown Norway rats on health span.
Specifically, we examined muscle mitochondrial permeability
transition pore opening and protein carbonylation as well as
muscle cellular nucleic acid oxidation and functional outcome to
explore the effectiveness of EufortynH on anti-aging aspects.
Materials and Methods
Animals and experimental procedures
The study was approved by the Institutional Animal Care and
Use Committee at the University of Florida. All procedures were
performed in accordance with the National Institutes of Health
guidelines for the care and use of laboratory animals. Forty-seven
Fischer 344 x Brown Norway (F344BNF1) male rats were
obtained from the National Institute of Aging colony (Indianapolis,
IN) and acclimated to the animal housing room of the University
of Florida for 2 weeks. The rats were housed individually in a
temperature (2062uC) and light-controlled environment (12-hour
light/dark cycle) with regular rat chow and water available ad
libitum. The treatment started after acclimation by adding
EufortynH compounded in a highly palletable food pellet (see
next detailed section on composition and supplementation). After
four weeks’ of treatment, grip strength was measured. During the
last week of the experimental period, rats were housed in
metabolic cages for urine collection. Collected urine was
immediately aliquoted and stored at 280uC until analysis. Finally,
rats were euthanized by rapid decapitation for collection of trunk
blood and skeletal muscle after six weeks’ of treatment. Body
weights were measured weekly and health status was checked by a
veterinarian daily.
Composition of the nutritional mixture and
supplementation pellet preparation
The commercially available nutritional mixture, EufortynH,
supplied by Pharmaland SA, Republic of San Marino, was used
(Table 1). The main ingredients are CoQ10 (5.3 mg/g of dry
powder) creatine (56.7 mg/g) and ginseng (21.7 mg/g). Coenzyme
Q10 in the mixture is present as the terclatrate, Q-terH, in which
CoQ10 stands in a 1:9 ratio with a pharmaceutically inactive
matrix. Q-terH itself is a multicomposite substance, obtained
through the mechano-physical procedure called terclatration,
whereby CoQ10 is embedded in the matrix and rendered highly
water soluble without chemical modifications of the moiety [34].
The EufortynH supplementation food pellets and control bacon
flavour pellets for the animals were prepared by Bio-Serv
(Frenchtown, NJ) utilizing an effective bacon flavour masking
capability in a grain-based diet (Table 2). A standard dose of 5
gram pellet contained EufortynH ingredients of 5 mg of tercla-
trated CoQ10 (Q-terH), 53 mg of creatine, and 20 mg of ginseng
extract. Each rat received approximately one supplementation
pellet (EufortynH or control) every day and pellet size was adjusted
daily according to the body weight of individual animal to ensure
that the rat received proper dose of EufortynH (Table 2). The
following daily dosage: 10 mg/kg of terclatrated CoQ10,
Nutraceutical and Performance
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were administered for six weeks.
Grip strength
Forelimb grip strength was measured using an automated grip
strength meter (Columbus Instruments, Columbus, OH) [55–57].
The grip force technique has been validated in many studies
assessing muscular function during drug treatment or pathologies
[58,59]. It is also an indicator of muscle strength and it correlates
significantly with sarcopenia and mortality [55,57,60]. For this
procedure, the experimenter grasped the rat by the tail and
suspended it above a grip ring. After about 3 sec, the animal was
gently lowered toward the grip ring and allowed to grasp the ring
with its forepaws. The experimenter then quickly lowered the
body to a horizontal position and tugged the tail until its grasp of
the ring was broken. The mean force in grams was determined
with a computerized electronic pull strain gauge fitted directly to
the grasping ring, and was divided by body mass. Average
measurements from three (3) successful trials were taken as the
final outcome. Successful trials were defined as those in which the
animal grasped the ring with both forepaws and pulled the ring
without jerking. Grip strength results were expressed as total grip
strength force divided by body weight (kg of force/kg body
weight).
Muscle mitochondria isolation
Characterization of age-related changes to mitochondria has
been complicated by the fact that two distinct populations of
mitochondria exist. Subsarcolemmal mitochondria (SSM) are
located beneath the plasma membrane, while interfibrillar
mitochondria (IFM) are found in parallel rows between the
myofibrils [61]. Gastrocnemius muscle was quickly removed and
tissue weights were recorded. IFM and SSM were isolated as
described previously [18]. Briefly, after removing fat and tendons,
gastrocnemius muscle (,2.3 g) was minced in ice-cold isolation
buffer (75 mM KCl, 150 mM sucrose, 1 mM EGTA, 5 mM
MgCl2, 50 mM Tris-HCl, 1 mM KH2PO4, and 0.4% fatty acid-
free BSA, pH 7.4 at 4uC), followed by homogenization in 10 ml
buffer per gram of tissue on ice, using five full strokes with a
mechanically driven Potter-Elvehjem glass-Teflon homogenizer.
Homogenates were centrifuged (8006g, 10 min, 4uC) to separate
large organelles and filaments containing IFM. The supernatant
containing SSM was filtered through synthetic cheese cloth to
avoid contamination with cell debris and was centrifuged
(8,0006g, 10 min, 4uC) to obtain the SSM fraction. The initial
IFM-containing pellet was immediately resuspended in 10 ml
isolation buffer. IFM were released from myofibrils via incubation
on ice with freshly prepared protease (0.5 U/g tissue; Sigma-
Aldrich, St. Louis, MO) for 1 min with agitation. After five strokes
of homogenization, large organelles and nuclei were removed by
centrifugation (8006g, 10 min, 4uC). The supernatant containing
IFM was filtered through cheese cloth and centrifuged (8,0006g,
10 min, 4uC) to collect the IFM pellet. The IFM and SSM pellets
were gently resuspended in BSA-free buffer, centrifuged twice and
kept on ice for the mitochondrial calcium retention capacity assay.
Mitochondrial calcium retention capacity measurement
The maximum amount of Ca
2+ required for mitochondrial PTP
opening was measured on freshly isolated IFM and SSM using the
fluorescent probe calcium green-5N (Molecular Probes, Eugene,
OR) as described previously [18,61]. IFM (0.2 mg/ml) and SSM
(0.5 mg/ml) were incubated with 250 ml of mitochondrial PTP
working buffer (250 mM sucrose, 10 mM KH2PO4 and 25 mM
Tris-HCl, pH 7.4 at 37uC). The reaction was kept at 37uC and
energized with 5 ml of substrate (0.5 M glutamate and 0.25 M
malate). A Synergy HT multidetection microplate reader (Bio-
TeK Instruments, Vinooski, VT) with automatic injectors was
used to inject 1.25 nmol CaCl2 into each well, with a 1-min
interval between injections. During this time, extra-mitochondrial
Ca
2+ pulses were recorded in the presence of 1 mM calcium green-
5N, with excitation and emission wave lengths set at 506 and
532 nm, respectively. Ca
2+ injection was continued until mito-
chondrial PTP completely opened. In a parallel assay, 0.5 mMo f
cyclosporin A (Sigma, St. Louis, MO) was used to confirm the
release of Ca
2+ in response to mitochondrial PTP opening [62].
Mitochondrial protein carbonyl assay
Mitochondrial protein carbonyls were measured using a commer-
cial ELISA (Biocell PC Test, Papatoetoe, New Zealand), following
the manufacturer’s instructions. In each well, 10 mgo fm i t o c h o n d r i a l
protein was loaded and the final absorbance was read at 450 nm
Table 1. The composition of EufortynH powder used for
integration into animal supplementation pellets by Bio-Serv.
Ingredients Content (mg/g)
Q-terH 5.3
Creatine 56.7
Ginseng panax root extract 21.7
Nicotinamide (Vit PP) 1.7
Calcium panthotenate (Vit B5) 0.7
Riboflavin (Vit B2) 0.3
Thiamine hydrocloride (Vit B1) 0.2
Piridoxin hydrochloride (Vit B6) 0.2
Cianocobalamine (Vit B12) 0.2610
23
Magnesium aspartate 40.7
Potassium aspartate 40.7
Sucrose 83.3
The EufortynH supplementation food pellets and control bacon flavour pellets
for the animals were prepared by Bio-Serv (Frenchtown, NJ) utilizing an
effective bacon flavour masking capability in a grain-based diet.
doi:10.1371/journal.pone.0010572.t001
Table 2. The ingredients of EufortynH and control pellets
supplemented to rats.
Ingredients (mg/pellet) Control EufortynH
Q-terH 05
Creatine 0 53
Ginseng 0 20
Protein 1055 1055
Fat 200 200
Carbohydrates 2750 2750
Fiber 200 200
Ash 335 335
Moisture ,500 ,500
Each rat received approximately one supplementation pellet (EufortynH or
control diet) daily for 6 weeks before euthanasia and pellet size was adjusted
daily according to the body weight of each individual animal to ensure that a
constant dose of EufortynH was administrated.
doi:10.1371/journal.pone.0010572.t002
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Device, Sunnyvale, CA). The protein carbonyl levels (nmol/mg) were
calibrated against oxidized protein standards provided.
Measurement of RNA and DNA oxidation using HPLC-
ECD
Oxidative RNA and DNA was quantified as 8-oxo-7,8-
dihydroguanosine/10
6 guanosine and 8-oxo-7,8-29-deoxyguano-
sine/10
6 deoxyguanosine using a HPLC-ECD method [2,56,63].
This procedure is based on high-salt nucleic acid release from
proteins, followed by removal of proteins and fats by organic
solvents at neutral pH, all in the presence of the metal chelator
deferoxamine mesylate (DFOM) at 0uC. Muscle pieces were
thawed, stripped for tendons on ice, weighed (,150 mg), minced,
and homogenized on slush ice using a glass-glass Duall
homogenizer in 2 ml (1:10 w:v) buffer (3 M guanidine thiocya-
nate (GTC), 0.2% (w/v) N-lauroylsarcosinate, 20 mM Tris,
pH 7.5) containing 10 mM freshly prepared DFOM. After
transferring the solution into phase-lock gel (PLG) tubes, an
equal volume of phenol/chloroform/isoamyl alcohol (25:24:1,
pH 6.7) was added and the samples were immediately vortexed,
followed by a 10 min vortexing period at 0uC to completely
release nucleic acids as previously described [63]. After
centrifugation (4,5006g,5 m i n ,0 uC), the aqueous phase was
transferred into a new PLG tube and extracted with an equal
volume of chloroform/isoamyl alcohol (24:1). The samples were
hand-shaken, centrifuged, and the aqueous phase was collected
and nucleic acids were precipitated by addition of an equal
amount of isopropanol. After centrifugation (10,0006g,1 0m i n ,
0uC), nucleic acids were washed with 70% (v/v) ethanol, dried,
dissolved in DNAse and RNase-free water containing 30 mM
DFOM, and hydrolyzed using 4 U nuclease P1 and 5 U alkaline
phosphatase in buffer (30 mM sodium acetate, 20 mMZ n C l 2,
pH 5.3) at 50uC for 60 min. After filtration, the samples were
analyzed by high-performance liquid chromatography coupled to
electrochemical and UV detection (HPLC-ECD/UV).
Total urine antioxidant power
Total urine antioxidant power was measured by using
NEOGEN calorimetric assay kits (Neogen Corporation, Lexing-
ton, KY). The assay uses antioxidants provided by the urine
samples or uric acid standards to reduce Cu(II) to Cu(I). The
reduced form of copper selectively reacts with the chromogenic
reagent to form a complex, which is stable and has an absorption
maximum at 450 nm. Total urine antioxidant power was
calibrated against uric acid standards provided with kits. Protein
concentration was assayed with the Bradford method using bovine
serum albumin as the standard [64]. Data were expressed as mmol
uric acid equivalents per mg urine protein.
Ferric reducing antioxidant power in plasma and muscle
tissue
The ferric reducing antioxidant power (FRAP) assay was
performed according to Benzie and Strain [65]. The principle of
the assay is based on the reduction of the Fe
3+-2,4,6-tripyridyl-S-
triazine complex to the ferrous form (Fe
2+). The antioxidant
activity of gastrocnemius muscle homogenate (1:10 w:v) or plasma
was measured by monitoring the change in absorption at 593 nm.
Acetate buffer (0.3 M, pH 3.6) was prepared by dissolving 3.1 g
C2H3O2NaN3H2O and 16 ml acetic acid in 1 liter double-distilled
water. 2,4,6-Tripyridyl-S-triazine solution was prepared by
dissolving 10 mmol in 1 liter 40 mM HCl solution. Ferric solution
(20 mmol/l) was prepared using FeCl3N6H2O. The final working
FRAP reagent was prepared freshly by mixing acetate buffer,
2,4,6-tripyridyl- S-triazine and ferric solutions at a ratio of 10:1:1
(by vol.). In brief, 200 ml FRAP working reagent were incubated at
37uC in Spectramax 340 microplate spectrophotometer for
30 min. The reagent blank reading was recorded at 593 nm
followed by adding 10 ml plasma or muscle homogenate. The
absorbance was taken at 20 min when the reading was constant.
The difference in absorbance between the tested sample and the
blank reading was calculated and the data were calibrated with
ferrous standards and expressed as mM.
Statistical analysis
R e s u l t sa r ee x p r e s s e da sm e a n s6 SEM. Statistical analyses
were performed using GraphPad Prism Version 4.0 (GraphPad
Software, San Diego, CA). For outcome measures, effects were
assessed using a one-way ANOVA with age (8, 21, and 29) as a
factor in control groups and a two-way ANOVA with
treatment (EufortynH and control) and age (21 and 29) as
factors. Where appropriate, post-hoc effects were analyzed
using a Tukey’s multiple comparison test. Significance was set
at p,0.05. There was no statistical difference unless indicated
otherwise.
Results
Food intake
Food intake increased with age (age, p,0.05, one-way
ANOVA). However, there was no significant difference in food
intake between EufortynH treated rats and their age-matched
counterparts (Table 3).
Body weight
Body weight was significantly different between 8 and 21
months of age (p,0.05, Tukey’s multiple comparison test), but did
not show further change between 21 and 29 months of age in
control animals (Table 3). EufortynH supplement did not affect
body weight in rats at both 21 and 29 months of age as compared
with their age-matched control groups.
Muscle mass
Across the ages tested, there were differences in muscle mass as
measured in the gastrocnemius, plantaris, quadriceps, soleus and
extensor digitorum longus (EDL) muscles (age, p,0.05, one-way
ANOVA) (Table 3). Post-hoc analysis indicated that quadriceps,
gastrocnemius and plantaris muscle groups, the major antigravity
extensor muscles of the hindlimb, weighed significantly less in 29-
month-old rats than in 21-month-old rats (p,0.05, Tukey’s
multiple comparison test). In addition, the mass of EDL (fast-
twitch) and soleus (slow-twitch) muscles showed significant age-
associated reductions. Overall, EufortynH supplementation did not
affect muscle mass in rats at both 21 and 29 months of age as
compared with their age-matched control groups.
Grip strength
In the control groups, there was a significant age-associated
decline in grip strength (age, p,0.01, one-way ANOVA) with a
23% decrease at 21 months (p,0.01, Tukey’s multiple comparison
test) and a 24% decrease at 29 months (p,0.01, Tukey’s multiple
comparison test) as compared to 8-month-old rats (Fig. 1). There
was a significant attenuation of declining grip strength (p,0.05,
Tukey’s multiple comparison test) in 21-month-old rats fed
EufortynH as compared to age-matched controls. There was no
difference in grip strength, however, between control and
EufortynH groups at 29 months of age.
Nutraceutical and Performance
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2+ retention capacity in muscle SSM and IFM
The maximum amount of Ca
2+ required for mitochondrial PTP
opening was measured on freshly isolated IFM and SSM. The
calcium retention capacity of the SSM decreased significantly with
age in control rats at 8, 21 and 29 months of age (age, p,0.05,
one-way ANOVA) (Fig. 2A). No age-associated changes in the
IFM, however, were observed in control groups (Fig. 2B).
EufortynH supplement could significantly increase Ca
2+ retention
capacity of SSM in the muscle of 21-month-old rats as compared
to their age-matched counterparts (p,0.05, Tukey’s multiple
comparison test). However, EufortynH did not affect Ca
2+
retention capacity of SSM in the muscle of 29-month-old rats as
well as that of IFM in the muscle of 21- and 29-month-old rats.
Protein carbonyl levels in muscle SSM and IFM
The levels of protein carbonyls significantly increased in SSM
during the aging process in control cohorts (age, p,0.05, one-way
ANOVA) (Fig. 3A). Although the protein carbonyl levels in the
SSM of 21-month-old control rats did not show any increase in
comparison with that of 8-month-old control rats, SSM protein
carbonyl levels significantly increased between 21- and 29-month-
old control rats (p,0.05, Tukey’s multiple comparison test).
EufortynH could significantly lower the increase of protein
oxidation in SSM in the muscle of 29-month-old rats (p,0.05,
Tukey’s multiple comparison test). Two-way ANOVA analysis
indicated that there was a significant interaction of main effects
(p,0.05) and it showed that the effects of EufortynH treatment
depended on the age of the rats. Conversely, age and EufortynH
supplementation did not affect the protein carbonyl levels in IFM
(Fig. 3B).
Nucleic acid oxidative damage in gastrocnemius muscle
There was a trend (p=0.09, Tukey’s multiple comparison
test) for greater level of RNA oxidation in gastrocnemius muscle
of 29-month-old control rats as compared to 8-month-old
controls (Fig. 4A). In contrast, the RNA oxidation levels
remained fairly constant with age within EufortynH groups and
there was a significant decrease (p,0.05, Tukey’s multiple
comparison test) in muscle RNA oxidation in 29-month-old rats
fed EufortynH in comparison to that of their age-matched
counterparts. In control groups, the DNA oxidation levels did
not change significantly over the course of aging (Fig. 4B).
Two-way ANOVA indicated a tendency for DNA oxidation
levels to be lower in rats fed EufortynH compared to control rats
(treatment, p=0.07).
Total urine antioxidant power
The total urine antioxidant power in control groups decreased
with age (age, p,0.0001, one-way ANOVA) (Table 4). Post-hoc
analysis indicated that total urine antioxidant power in 29-month-
old rats was remarkably lower than that in 8- and 21-month-old
rats (p,0.001, Tukey’s multiple comparison test). In contrast,
EufortynH significantly increased the total urine antioxidant power
in 29-month-old rats as compared to age-matched control
(p,0.001, Tukey’s multiple comparison test) (Table 4).
Ferric reducing antioxidant power in muscle tissue and
plasma
In agreement with the total antioxidant results in the urine,
there was a 35% increase in the FRAP of gastrocnemius muscle
Figure 1. EufortynH supplementation affected grip strength in
rats at 21 months of age. In the control groups, there was a
significant age-related decline in grip strength (age, p,0.01, one-way
ANOVA). Post-hoc analysis showed a decline in 21- and 29-month-old
rats (**p,0.01, Tukey’s multiple comparison test) as compared to 8-
month-old control cohort. There was a significant increase in grip
strength in 21-month-old rats fed EufortynH as compared to their age-
matched controls after 4 weeks of treatment (
#p,0.05, Tukey’s multiple
comparison test). Values are means 6 SEM (n=7214).
doi:10.1371/journal.pone.0010572.g001
Table 3. Baseline chow intake, body and muscle weights for male F344BNF1 rats.
Age (months) 8 21 21 29 29
Group Control Control EufortynH Control EufortynH
BW (g) 405612
a 518613
b 523610
b 518619
b 556618
b
N7 1 4 1 3 7 7
Food intake (g/day) 16.760.7
a 18.960.4
ab 19.060.5
ab 19.761.1
b 20.860.8
b
Gastrocnemius/BW (mg/g) 5.3160.06
c 4.1160.12
b 4.0060.14
b 3.1060.11
a 3.0360.11
a
Plantaris/BW (mg/g) 1.0260.02
c 0.8960.03
b 0.8960.02
b 0.7060.06
a 0.6860.04
a
Quadriceps/BW (mg/g) 7.8060.36
c 6.4460.18
b 6.2160.19
b 5.3060.26
a 5.2660.18
a
Soleus/BW (mg/g) 0.4160.01
b 0.3860.02
b 0.3660.01
b 0.3060.02
a 0.3160.01
a
EDL/BW (mg/g) 0.4460.01
c 0.3760.01
b 0.3760.01
b 0.2960.02
a 0.3060.00
a
Values are means 6 SEM (n=7214).
a,b,cDifferent letters are significantly different from each other (p,0.05 by Tukey’s Multiple Comparison Test). EufortynH did not affect body and muscle weights, as well
as food intake at 21 and 29 months of age. The muscle weight is reported as the average weight of muscles from two legs. Abbreviations: BW, body weight; EDL:
extensor digitorum longus muscle.
doi:10.1371/journal.pone.0010572.t003
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age-matched counterparts (Table 5). Moreover, EufortynH
supplementation increased plasma FRAP by 15% in 29-month-
old rats (Table 6), indicating an augmented antioxidant power
in tissues and cells. However, there was no statistical difference
in muscle and plasma FRAP due to the low sample size. Most
sample specimens were utilized, for example we only had 3
samples left in 29-month-old control cohort (Table 5 and 6).
Discussion
The purpose of this study was to assess the effects of EufortynH
supplementation on oxidative stress, mitochondrial function and
physical performance. We have demonstrated that EufortynH
significantly attenuates declining physical performance and improves
Ca
2+ retention capacity of SSM in 21-month-old rats. Moreover, the
a g e - r e l a t e di n c r e a s ei nc e l l u l a rR N Ao x i d a t i o na n dp r o t e i no x i d a t i o n
in SSM was significantly ameliorated by EufortynH. These findings
suggest that EufortynH may improve homeostatic regulation of
cellular and mitochondrial oxidative stress, mitochondrial function
and physical performance if initiated at early middle age.
Functional aging and grip strength
The consequences of the aging process in skeletal muscles are
characterized by a decline in physiological function and a loss of
muscle strength, a condition incapable of performing strenuous
physical work [66]. The term ‘‘functional age’’, therefore, is a
reliable index of the most vulnerable subset of older individuals
[67,68]. The primary outcome variable of this study was grip
strength. In both humans and rodents, grip strength is one of most
Figure 2. EufortynH significantly improved the calcium retention capacity in muscle subsarcolemmal mitochondria (SSM) in 21-
month-old rats. (A) The maximum amount of Ca
2+ required for mitochondrial PTP opening was measured on freshly isolated IFM and SSM. The
calcium retention capacity of the SSM for control rats at 8, 21 and 29 months of age decreased significantly with age (age, p,0.05, one-way ANOVA).
However, the decrease in the calcium uptake capacity in SSM of 21-month-old rats was significantly ameliorated by EufortynH supplementation
(
#p,0.05, Tukey’s multiple comparison test). (B) The calcium retention capacity of IFM for rats at 8, 21, and 29 months of age did not change over
time and there was no statistical difference in the IFM calcium uptake capacity between control and treatment animals at 21 and 29 months of age.
Values are means 6 SEM (n=7214).
doi:10.1371/journal.pone.0010572.g002
Figure 3. EufortynH supplementation significantly decreased the subsarcolemmal mitochondria (SSM) protein carbonyl
concentration in 29-month-old rats as compared to the age-matched control cohort. (A) SSM protein carbonyl concentrations increased
with age (age, p,0.05, one-way ANOVA). There was a significant difference in the SSM protein carbonyl concentration between 21- and 29-month-
old control groups (*p,0.05, Tukey’s multiple comparison test). EufortynH significantly ameliorated the protein carbonyl levels in SSM in 29-month-
old rats (
#p,0.05, Tukey’s multiple comparison test). (B) The protein carbonyl concentrations in IFM did not change over time for control animals.
Moreover, there was no treatment effect or interaction. Values are means 6 SEM (n=5210).
doi:10.1371/journal.pone.0010572.g003
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previous studies have shown that aged rats with advanced muscle
atrophy exhibited reduced grip strength [55,56]. In the present
study, muscle mass and grip strength decreased significantly with
age in control groups (Table 3). EufortynH supplementation
significantly ameliorated the decline in grip strength in 21-month-
old rats, however, did not have a significant effect when initiated in
29-month-old rats. This suggests there may be a critical time
period during which this nutritional combination is effective and
they may no longer be beneficial after a threshold is reached.
Another possibility is that the time period of EufortynH
supplementation (4 weeks while grip strength was measured and
total of 6 weeks in this study) and the dosage used were not
sufficient to achieve this goal in late middle aged animals.
Mitochondrial PTP opening in the gastrocnemius muscle
Mitochondrial oxidative stress and apoptotic cell death are
being increasingly recognized as fundamental driving mechanisms
of aging, especially in post-mitotic tissues [1,66,71]. The switch to
a cell death process can be mediated by opening of the
mitochondrial PTP, causing collapse of the membrane potential
and swelling [19]. Therefore, inhibition of pore opening is an
effective and promising strategy to modulate the aging process.
In the present study, gastrocnemius muscles were selected for
mitochondrial isolation and function measurement because (1) they
are one of the major antigravity extensor muscles of the hindlimb;
(2) the substantial amount of tissue allowed us to perform the
analysis; (3) forelimb and hindlimb grip force is positively
correlated in rodents [59]. Our current study clearly shows that
EufortynH efficiently mitigated the susceptibility of SSM to Ca
2+-
induced mitochondrial PTP opening and improved SSM function
in 21-month-old rats. Although the increase in forelimb muscle
force as assessed by grip strength cannot be directly linked to the
improved muscle mitochondrial calcium handling capacity ob-
served in the hindlimb muscle, it is remarkable that both grip
strength and mitochondrial Ca
2+ handling capacity increased by
EufortynH supplementation in 21-month-old rats.
Consistent with our previous study [18], we also found that there
was a significant age-associated decrease in mitochondrial Ca
2+
r e t e n t i o nc a p a c i t yi nS S M ,b u tn o ti nI F M .P o s t - h o ca n a l y s i s
indicated that the SSM isolated from late middle aged rat muscle
have a significant lower Ca
2+ retention capacity than those from
young rat muscle, whereas the IFM Ca
2+ retention capacity
remained fairly constant within all age cohorts. Indeed, various
studies have shown that the IFM and SSM differ in intracellular
localization and function [72–75]. For instance, Adhihetty et al. have
measured how fast the PTP in IFM and SSM opened in response to
excessive Ca
2+ and oxidative stress and they found that IFM
exhibited a greater ‘‘Time to Vmax’’ compared to SSM, indicating
that IFM were more resistant to Ca
2+-induced PTP opening than
SSM [72]. This is in agreement with our results, suggesting that the
two subpopulations differ in function measurements.
Oxidative stress in the gastrocnemius muscle
Protein carbonyl content is one of the most widely used
oxidative markers and increased levels of protein carbonyls have
been reported in patients with diabetes [76], breast cancer [77]
and aging [78]. Recently, age-related increase in total mitochon-
Figure 4. RNA and DNA oxidative damage in gastrocnemius muscle. (A) Post-hoc analysis showed that there is a tendency for greater level
of RNA oxidation in 29-month-old rats compared to 8-month-old control (p=0.09, Tukey’s multiple comparison test). In addition, EufortynH
significantly decreases RNA oxidative damage in 29-month-old rats (
#p,0.05, Tukey’s multiple comparison test). (B) DNA oxidative damage did not
change over time for control animals. Values are means 6 SEM (n=728).
doi:10.1371/journal.pone.0010572.g004
Table 4. Total urine antioxidant power for male F344BNF1 rats.
Age (months) 8 21 21 29 29
Group Control Control EufortynH Control EufortynH
mmol uric acid equivalent per mg protein 3.5660.07
b 3.1660.15
b 3.5360.09
b 1.5760.17
a 3.8660.10
b
Values are means 6 SEM (n=327).
a,bDifferent letters are significantly different from each other (p,0.001 by Tukey’s Multiple Comparison Test).
doi:10.1371/journal.pone.0010572.t004
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in rats, showing that carbonyl levels in skeletal muscles are
associated with reactive oxygen species produced in mitochondria
[79]. Supportively, our results indicate that the SSM protein
carbonyl levels was significantly elevated in 29-month-old rat
gastrocnemius muscles and EufortynH supplementation remark-
ably ameliorated the increase in SSM protein carbonyl levels.
Recently, Barreiro and Hussain have fully documented the
association between elevated protein carbonylation and depressed
skeletal muscle performance [80]. There is evidence of skeletal
muscle immobilization and elevated protein carbonylation in
rodents undergoing mechanical ventilation [81,82]. The observa-
tion that administration of antioxidants significantly mitigated
mechanical ventilation-induced contractile dysfunction and pro-
tein carbonylation further underlines the importance of antiox-
idant defense [83,84].
Accordingly, oxidative damage to DNA and RNA in the
gastrocnemius muscle was assessed as their oxidation products
simultaneously. We found that muscle RNA oxidative damage
product has the tendency to increase at 29 month of age. The
functional consequences of increased RNA oxidative damage in
skeletal muscles could be serious and even causative to muscle
contraction and atrophy [2,85]. Therefore, the decline in grip
force in 29-month-old control rats may be related to the increased
SSM protein and RNA oxidation levels in the gastrocnemius
muscle.
Total urine antioxidant power and plasma ferric reducing
antioxidant power
The decrease in total antioxidant power in plasma or body
fluids has been implicated in the aging process and a number of
diseases [86–88]. For instance, Leeuwenburgh et al. reported an
age-related increase in urinary oxidized amino acids in rats and
antioxidant supplementation partly attenuated the increase [89].
Thus, total antioxidant capacity measurements can provide the
integrated characteristics of endogenous redox potential and also
give a further insight into the effectiveness of dietary modulation in
vivo on redox status [90,91]. We have confirmed that there was a
significant decrease in total urine antioxidant power in late middle
aged rats; however, the decrease was completely reserved by
EufortynH. The data imply that EufortynH is effective in exerting
its antioxidant capacity and modulating in vivo redox status, not
only in the skeletal muscle, but also in the metabolic system.
Moreover, the changes in total urine antioxidant power as well as
in plasma and muscle FRAP after supplementation may provide
information on the absorption and bioavailability of nutritional
compounds, suggesting that EufortynH can be effectively absorbed
and its metabolites excreted in the urine.
EufortynH, by virtue of its antioxidant capacity, significantly
decreased the SSM protein carbonyl levels and muscle RNA
oxidative damage in 29-month-old rats. Consistently, the decrease
of total urine antioxidant power in 29-month-old rats was
mitigated by EufortynH supplementation, suggestion that Eufor-
tynH exerts potent antioxidant activity and was distributed
throughout the circulation. However, it failed to completely
reverse the loss of grip strength decrease in 29-month-old rats,
suggesting that other causal factors are likely to be involved and
more studies are warranted to investigate the effective dosage and
supplementation time period of EufortynH in late middle aged
animals.
Conclusions
The current study provides striking results concerning the
potential benefits of EufortynH used to combat age-related
mitochondrial dysfunction. Gastrocnemius muscle mitochondrial
function and grip strength were improved in 21-month-old rats fed
EufortynH compared with their age-matched counterparts. In
addition, muscle mitochondrial protein oxidation (carbonyl
formation), oxidative stress to RNA, and the age-associated
decline of total urine antioxidant power were remarkably
attenuated by EufortynH supplementation in 29-month-old rats.
Our current study suggests that EufortynH is a potent antioxidant
and has the potential to improve health span. Future clinical
studies should explore the potential benefits of EufortynH on
physical function, clinical outcomes, as well as its ability to reduce
oxidative stress levels, in middle-aged and older adults.
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Table 5. Ferric reducing antioxidant power (FRAP) of
gastrocnemius muscle homogenate in 8- and 29-month-old
control rats and in 29-month-old EufortynH treated rats.
Age (months) 8 29 29
Group Control Control EufortynH
N4 3 6
FRAP value (mM) 0.22860.020 0.20560.002 0.27660.036
Values are means 6 SEM (n=326). Note the small sample size in the 29-month
control group, which limits the statistical power of this particular analysis. This
was due to the limited remaining sample availability (See results).
doi:10.1371/journal.pone.0010572.t005
Table 6. Ferric reducing antioxidant power (FRAP) of plasma in 8-month-old control rats and in 21- and 29-month-old rats fed
either control or EufortynH pellets.
Age (months) 8 21 21 29 29
Group Control Control EufortynH Control EufortynH
N 6 663 4
FRAP value (mM) 0.39360.008 0.39560.009 0.40860.025 0.31460.024 0.36060.004
Values are means 6 SEM (n=326). Note the small sample size in the 29-month control group, which limits the statistical power of this particular analysis. This was due
to the limited remaining sample availability (See results).
doi:10.1371/journal.pone.0010572.t006
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